288 related articles for article (PubMed ID: 29928279)
1. Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells.
Sacchi A; Tumino N; Sabatini A; Cimini E; Casetti R; Bordoni V; Grassi G; Agrati C
Front Immunol; 2018; 9():1271. PubMed ID: 29928279
[TBL] [Abstract][Full Text] [Related]
2. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals.
Ryan PL; Sumaria N; Holland CJ; Bradford CM; Izotova N; Grandjean CL; Jawad AS; Bergmeier LA; Pennington DJ
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14378-14383. PubMed ID: 27911793
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cells Are Critical for the Activation and Expansion of Vδ2
Wang X; Liu J; Gao H; Mo XD; Han T; Xu LP; Zhang XH; Huang XJ
Front Immunol; 2018; 9():2528. PubMed ID: 30443256
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.
Fisher JP; Yan M; Heuijerjans J; Carter L; Abolhassani A; Frosch J; Wallace R; Flutter B; Capsomidis A; Hubank M; Klein N; Callard R; Gustafsson K; Anderson J
Clin Cancer Res; 2014 Nov; 20(22):5720-32. PubMed ID: 24893631
[TBL] [Abstract][Full Text] [Related]
6. Suppressive activity of Vδ2
Schilbach K; Krickeberg N; Kaißer C; Mingram S; Kind J; Siegers GM; Hashimoto H
Cancer Immunol Immunother; 2020 Apr; 69(4):593-610. PubMed ID: 31982940
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy accelerates immune-senescence and functional impairments of Vδ2
Bruni E; Cazzetta V; Donadon M; Cimino M; Torzilli G; Spata G; Leonardi G; Dieli F; Mikulak J; Mavilio D
J Immunother Cancer; 2019 Dec; 7(1):347. PubMed ID: 31829255
[TBL] [Abstract][Full Text] [Related]
8. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
9. CD4+ CD25(high) Foxp3+ regulatory T cells downregulate human Vdelta2+ T-lymphocyte function triggered by anti-CD3 or phosphoantigen.
Mahan CS; Thomas JJ; Boom WH; Rojas RE
Immunology; 2009 Jul; 127(3):398-407. PubMed ID: 19019089
[TBL] [Abstract][Full Text] [Related]
10. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
11. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
Knight A; Mackinnon S; Lowdell MW
Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
[TBL] [Abstract][Full Text] [Related]
12. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer.
Ma P; Beatty PL; McKolanis J; Brand R; Schoen RE; Finn OJ
Front Immunol; 2019; 10():1401. PubMed ID: 31275327
[TBL] [Abstract][Full Text] [Related]
13. Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation.
Bian Z; Abdelaal AM; Shi L; Liang H; Xiong L; Kidder K; Venkataramani M; Culpepper C; Zen K; Liu Y
Eur J Immunol; 2018 Jun; 48(6):1046-1058. PubMed ID: 29488625
[TBL] [Abstract][Full Text] [Related]
14. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract][Full Text] [Related]
15. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
16. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus drives Vδ2neg γδ T cell inflation in many healthy virus carriers with increasing age.
Alejenef A; Pachnio A; Halawi M; Christmas SE; Moss PA; Khan N
Clin Exp Immunol; 2014 Jun; 176(3):418-28. PubMed ID: 24547915
[TBL] [Abstract][Full Text] [Related]
18. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
[TBL] [Abstract][Full Text] [Related]
20. Long-term use of interferon-β in multiple sclerosis increases Vδ1
Maimaitijiang G; Watanabe M; Shinoda K; Isobe N; Nakamura Y; Masaki K; Matsushita T; Yoshikai Y; Kira JI
J Neuroinflammation; 2019 Sep; 16(1):179. PubMed ID: 31519178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
